Sign in
BMEA Stock Price, Chart, Stats & News
Biomea Fusion, Inc.
Save
74.37M
Market cap
–
Current P/E
–
Forward P/E
BMEA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -105.51% |
ROE | -243.73% |
D/E | 0.05x |
Interest coverage ratio | – |
BMEA valuation
P/E | – |
P/S | – |
P/B | 3.23x |
P/CF | -1.36x |
P/FCF | -1.12x |
P/OCF | -1.36x |
PEG | -0.04x |
EV multiple | -1.72x |
About
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration.
Similar securities
Based on sector and market capitalization
Report issue